Compare NVAX & CENT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | CENT |
|---|---|---|
| Founded | 1987 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 1996 | 1996 |
| Metric | NVAX | CENT |
|---|---|---|
| Price | $12.78 | $40.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $14.00 | ★ $53.00 |
| AVG Volume (30 Days) | ★ 6.6M | 60.3K |
| Earning Date | 11-05-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 309.76 | 57.41 |
| EPS | N/A | ★ 2.84 |
| Revenue | $1,123,479,000.00 | ★ $3,129,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $14.28 |
| Revenue Growth | ★ 64.69 | N/A |
| 52 Week Low | $6.20 | $28.77 |
| 52 Week High | $13.39 | $46.97 |
| Indicator | NVAX | CENT |
|---|---|---|
| Relative Strength Index (RSI) | 68.95 | 49.92 |
| Support Level | $7.64 | $39.61 |
| Resistance Level | N/A | $41.37 |
| Average True Range (ATR) | 0.97 | 0.85 |
| MACD | 0.11 | 0.25 |
| Stochastic Oscillator | 85.02 | 74.51 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.